Black Diamond Therapeutics, Inc.(BDTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BDTX Black Diamond Therapeutics, Inc.

Closed 06-08 16:00:00 EDT

1.85

-0.12

-6.09%

盘后1.85

+0.00+0.16%

19:46 EDT

High2.01	Low1.85	Vol1.11M
Open2.00	D1 Closing1.97	Amplitude8.33%
Mkt Cap105.98M	Tradable Cap72.60M	Total Shares57.29M
T/O2.14M	T/O Rate2.84%	Tradable Shares39.24M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BDTX","market":"US","secType":"STK","nameCN":"Black Diamond Therapeutics, Inc.","latestPrice":1.85,"timestamp":1780948800000,"preClose":1.97,"halted":0,"volume":1114102,"hourTrading":{"tag":"盘后","latestPrice":1.8529,"preClose":1.85,"latestTime":"19:46 EDT","volume":15881,"amount":29526.8117,"timestamp":1780962417701,"change":0.0029,"changeRate":0.001568,"amplitude":0.021622},"delay":0,"changeRate":-0.060913705583756285,"floatShares":39244252,"shares":57288750,"eps":-0.758237,"marketStatus":"Closed","change":-0.12,"latestTime":"06-08 16:00:00 EDT","open":2,"high":2.0092,"low":1.845,"amount":2135872.3511092,"amplitude":0.08335,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.758237,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1780992000000},"marketStatusCode":5,"adr":0,"listingDate":1580360400000,"exchange":"NASDAQ","adjPreClose":1.97,"preHourTrading":{"tag":"盘前","latestPrice":2.01,"preClose":1.97,"latestTime":"08:58 EDT","volume":14281,"amount":28287.9076232,"timestamp":1780923496634,"change":0.04,"changeRate":0.020305,"amplitude":0.035533},"postHourTrading":{"tag":"盘后","latestPrice":1.8529,"preClose":1.85,"latestTime":"19:46 EDT","volume":15881,"amount":29526.8117,"timestamp":1780962417701,"change":0.0029,"changeRate":0.001568,"amplitude":0.021622},"volumeRatio":1.143579,"impliedVol":1.27,"impliedVolPercentile":0.5618},"requestUrl":"/m/hq/s/BDTX","defaultTab":"news","newsList":[{"id":"2640952247","title":"Wedbush Remains a Buy on Black Diamond Therapeutics (BDTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640952247","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640952247?lang=en_us&edition=fundamental","pubTime":"2026-06-01 21:35","pubTimestamp":1780320947,"startTime":"0","endTime":"0","summary":"Wedbush analyst Robert Driscoll maintained a Buy rating on Black Diamond Therapeutics today and set a price target of $14.00. According to TipRanks...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wedbush-remains-a-buy-on-black-diamond-therapeutics-bdtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wedbush-remains-a-buy-on-black-diamond-therapeutics-bdtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BDTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637031909","title":"Black Diamond Therapeutics CEO joins Jefferies Global Healthcare Conference fireside chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2637031909","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637031909?lang=en_us&edition=fundamental","pubTime":"2026-05-22 20:02","pubTimestamp":1779451324,"startTime":"0","endTime":"0","summary":"Black Diamond Therapeutics will join the Jefferies Global Healthcare Conference in New York on June 3, 2026.CEO Mark Velleca will take part in a fireside chat scheduled for 4:55 p.m. to 5:25 p.m. ET.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nNDL198ltk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","SG9999014021.USD","SG9999014005.SGD","BDTX","LU2210150020.SGD","NDAQ","LU2210149790.SGD","IE00BKPKM429.USD","IE00BGHQF748.EUR","LU0314104364.USD","BK4585","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","BK4139","LU2095319765.USD","BK4588","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","BK4112","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637315629","title":"Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (ARWR), Black Diamond Therapeutics (BDTX) and Iovance Biotherapeutics (IOVA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2637315629","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637315629?lang=en_us&edition=fundamental","pubTime":"2026-05-22 18:30","pubTimestamp":1779445858,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Arrowhead Pharmaceuticals (ARWR), Black Diamond Ther...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-arrowhead-pharmaceuticals-arwr-black-diamond-therapeutics-bdtx-and-iovance-biotherapeutics-iova-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-arrowhead-pharmaceuticals-arwr-black-diamond-therapeutics-bdtx-and-iovance-biotherapeutics-iova-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","BK4585","LU0029874061.USD","XLV","BK4137","BK4139","HCSG","LABU","BK4588","ARWR","BK4581","LU0128526141.USD","IOVA","BDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637357657","title":"Black Diamond reports Phase 2 silevertinib mPFS 15.2 months in frontline EGFR-mutant NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2637357657","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637357657?lang=en_us&edition=fundamental","pubTime":"2026-05-22 05:14","pubTimestamp":1779398050,"startTime":"0","endTime":"0","summary":"Black Diamond Therapeutics reported positive Phase 2 results for silevertinib in first-line non-small cell lung cancer patients with non-classical EGFR mutations, with the data scheduled for presentation at ASCO on May 30, 2026.The study showed durable tumor control across a broad range of these mutations, supporting use as a frontline targeted option in an underserved patient group.Activity in the central nervous system was a key feature, with findings indicating strong control of existing brain disease and no new brain metastases during follow-up.The safety profile was described as manageable with dose adjustments, with the regimen for the next-stage program set at a lower daily dose.The company plans to engage the FDA later in 2026 to discuss a pivotal development strategy.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDL5B1TQz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BDTX","IE00B64PRP62.GBP","SG9999014021.USD","SG9999014039.USD","LU0314104364.USD","BK4112","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","BK4585","NDAQ","BK4139","IE00BGHQF748.EUR","LU2095319765.USD","IE00BKPKM429.USD","BK4588","LU2210149790.SGD","IE00BN0W2W23.USD","SG9999014013.SGD","LU2210150020.SGD","SG9999014005.SGD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637835768","title":"Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline Nsclc Patients With Egfr Non-Classical Mutations","url":"https://stock-news.laohu8.com/highlight/detail?id=2637835768","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637835768?lang=en_us&edition=fundamental","pubTime":"2026-05-22 05:13","pubTimestamp":1779398032,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nTUAC2T2XM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BDTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637607357","title":"Black Diamond Therapeutics Inc - 150 Mg Once Daily Dose Supported for Pivotal Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2637607357","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637607357?lang=en_us&edition=fundamental","pubTime":"2026-05-22 05:13","pubTimestamp":1779398032,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nTUAC2T2XM:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BDTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637357678","title":"Black Diamond Therapeutics Inc - Preliminary Median Pfs 15.2 Months; Median Duration of Response Not Reached","url":"https://stock-news.laohu8.com/highlight/detail?id=2637357678","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637357678?lang=en_us&edition=fundamental","pubTime":"2026-05-22 05:13","pubTimestamp":1779398032,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nTUAC2T2XM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637357624","title":"Black Diamond Therapeutics Inc - No New Safety Signals Observed; Adverse Event Profile Manageable","url":"https://stock-news.laohu8.com/highlight/detail?id=2637357624","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637357624?lang=en_us&edition=fundamental","pubTime":"2026-05-22 05:13","pubTimestamp":1779398032,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nTUAC2T2XM:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BDTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636855241","title":"Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2636855241","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636855241?lang=en_us&edition=fundamental","pubTime":"2026-05-19 20:00","pubTimestamp":1779192000,"startTime":"0","endTime":"0","summary":"Webcast will be held Thursday, May 21, 2026, at 5:30 p.m. ET CAMBRIDGE, Mass., May  19, 2026  (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company dev","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/19/3297411/0/en/Black-Diamond-Therapeutics-to-Host-Webcast-for-Investors-Highlighting-Updated-Results-from-Phase-2-Trial-of-Silevertinib-in-1L-EGFRm-NSCLC.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HST","BK4585","ISBC","BK4181","BK4139","BK4218","BK4588","BDTX","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634258128","title":"Black Diamond Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2634258128","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634258128?lang=en_us&edition=fundamental","pubTime":"2026-05-12 05:01","pubTimestamp":1778533305,"startTime":"0","endTime":"0","summary":"Black Diamond Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryBlack Diamond Therapeutics Inc BDTX.OQ reported a quarterly adjusted loss of 16 cents per share for the ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nL8N41O2LF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634460254","title":"Black Diamond Therapeutics Inc  expected to post a loss of 19 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2634460254","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634460254?lang=en_us&edition=fundamental","pubTime":"2026-05-09 06:19","pubTimestamp":1778278746,"startTime":"0","endTime":"0","summary":"Black Diamond Therapeutics Inc  expected to post a loss of19cents a share - Earnings Preview Black Diamond Therapeutics Inc BDTX.OQ BDTX.O is expected to  show no change in quarterly revenue when it r","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L2SI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BDTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633524141","title":"Black Diamond Therapeutics: Q1 EPS $-0.16","url":"https://stock-news.laohu8.com/highlight/detail?id=2633524141","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633524141?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:30","pubTimestamp":1778153401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nTUABLHNJL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633314949","title":"Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2633314949","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633314949?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:30","pubTimestamp":1778153400,"startTime":"0","endTime":"0","summary":"Oral presentation of silevertinib Phase 2 data in frontline EGFRm NSCLC patients, including preliminary DOR and PFS data, to take place at the 2026 ASCO Annual MeetingFirst patient dosed in the Phase ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3289874/0/en/Black-Diamond-Therapeutics-Reports-First-Quarter-2026-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFS","BK4139","BK4211","BK4195","BDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633414146","title":"Black Diamond Therapeutics Q1 FY26 net loss widens to $9.04 million; no revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2633414146","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633414146?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:23","pubTimestamp":1778152989,"startTime":"0","endTime":"0","summary":"Black Diamond Therapeutics posted a net loss of USD 9.04 million for the quarter ended March 31, 2026, swinging from net income of USD 56.54 million a year earlier.Revenue was no revenue versus USD 70 million a year earlier, reflecting the upfront payment received under the Servier agreement in first-quarter 2025.Research and development expense fell to USD 7 million from USD 10.51 million, while general and administrative expense declined to USD 4.26 million from USD 4.96 million.Cash, cash equivalents and investments totaled USD 118.3 million at March 31, 2026; management expects this to fund operations into the second half of 2028.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Black Diamond Therapeutics Inc. published the original ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL610Czz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631525694","title":"Olema appoints Prakash Raman to board of directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2631525694","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631525694?lang=en_us&edition=fundamental","pubTime":"2026-04-30 04:05","pubTimestamp":1777493140,"startTime":"0","endTime":"0","summary":"Olema Pharmaceuticals appointed Prakash Raman to board of directors.He previously served as CEO of Ribon Therapeutics.Earlier roles included chief business development officer at Flagship Pioneering, vice president and global head of NIBR business development and licensing at Novartis.Raman has been a director at Black Diamond Therapeutics since April 2024.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDL7PfsHc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","SG9999014013.SGD","SG9999014039.USD","SG9999014005.SGD","IE00BN0W2W23.USD","SG9999014021.USD","LU2210149790.SGD","IE00BKPKM429.USD","BK4585","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","BK4505","BK4588","IE00BGHQF748.EUR","OLMA","LU2095319765.USD","IE00BN0W2T93.GBP","LU0314104364.USD","NDAQ","BDTX","BK4139","LU2210150020.SGD","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629058362","title":"Black Diamond presents Phase 2 silevertinib data in frontline EGFR-mutant NSCLC at ASCO","url":"https://stock-news.laohu8.com/highlight/detail?id=2629058362","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629058362?lang=en_us&edition=fundamental","pubTime":"2026-04-21 22:40","pubTimestamp":1776782419,"startTime":"0","endTime":"0","summary":"Black Diamond Therapeutics scheduled new Phase 2 data for silevertinib  in treatment-nave non-small cell lung cancer patients with non-classical EGFR mutations for an oral presentation at ASCO 2026 on May 30.Presentation will highlight safety profile, with efficacy results intended to support positioning of silevertinib in a frontline setting for this mutation-defined group.Company also plans a Phase 2 poster at ASCO 2026 on May 31 covering previously treated EGFR-mutant non-small cell lung cancer, including non-classical mutations or C797S.Separate trial-in-progress poster on June 1 will outline a randomized Phase 2 study of silevertinib combined with temozolomide in newly diagnosed EGFRvIII-positive glioblastoma.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDL7dPF8B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","BK4112","SG9999014039.USD","NDAQ","SG9999014013.SGD","IE00BN0W2W23.USD","LU0314104364.USD","BK4585","LU2210149790.SGD","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","LU2210150020.SGD","LU2095319765.USD","IE00BKPKM429.USD","BK4588","SG9999014005.SGD","SG9999014021.USD","BK4139","IE00BN0W2T93.GBP","BDTX","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620628585","title":"Black Diamond Therapeutics (BDTX) Profit Swing To US$0.81 EPS Challenges Bearish Earnings Narratives","url":"https://stock-news.laohu8.com/highlight/detail?id=2620628585","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620628585?lang=en_us&edition=fundamental","pubTime":"2026-03-18 10:15","pubTimestamp":1773800105,"startTime":"0","endTime":"0","summary":"Black Diamond Therapeutics (BDTX) just posted a sharp swing into profit for FY 2025, with first half revenue of US$70 million translating to basic EPS of US$0.81, compared with losses in both halves of FY 2024. Over the past year, the company has seen revenue move from US$0 to US$70 million while basic EPS has shifted from losses of US$0.71 and US$0.56 in FY 2024 to a trailing 12 month figure of US$0.25. This sets up a results season where investors will focus squarely on how durable these...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bdtx/black-diamond-therapeutics/news/black-diamond-therapeutics-bdtx-profit-swing-to-us081-eps-ch","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bdtx/black-diamond-therapeutics/news/black-diamond-therapeutics-bdtx-profit-swing-to-us081-eps-ch","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620822429","title":"Stifel Nicolaus Keeps Their Buy Rating on Black Diamond Therapeutics (BDTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620822429","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620822429?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:15","pubTimestamp":1773746133,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Laura Prendergast maintained a Buy rating on Black Diamond Therapeutics today and set a price target of $8.00. Prendergast ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-keeps-their-buy-rating-on-black-diamond-therapeutics-bdtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-keeps-their-buy-rating-on-black-diamond-therapeutics-bdtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BDTX","SF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620268514","title":"Wedbush Lifts Price Target on Black Diamond Therapeutics to $14 From $13, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2620268514","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620268514?lang=en_us&edition=fundamental","pubTime":"2026-03-17 18:56","pubTimestamp":1773745015,"startTime":"0","endTime":"0","summary":"Black Diamond Therapeutics (BDTX) has an average rating of buy and mean price target of $9.43, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620122204","title":"Black Diamond Therapeutics (BDTX) Receives a Buy from TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2620122204","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620122204?lang=en_us&edition=fundamental","pubTime":"2026-03-17 11:25","pubTimestamp":1773717926,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Marc Frahm maintained a Buy rating on Black Diamond Therapeutics yesterday. The company’s shares closed yesterday at $2.19. Frahm ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/black-diamond-therapeutics-bdtx-receives-a-buy-from-td-cowen-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/black-diamond-therapeutics-bdtx-receives-a-buy-from-td-cowen-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4207","BK4139","TD","BDTX","BK4566","BK4127","COWN"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.blackdiamondtherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.1126},{"period":"1month","weight":-0.3014},{"period":"3month","weight":-0.0837},{"period":"6month","weight":-0.2622},{"period":"1year","weight":-0.2088},{"period":"ytd","weight":-0.1893}],"compareEarnings":[{"period":"1week","weight":-0.025},{"period":"1month","weight":0.0051},{"period":"3month","weight":0.0969},{"period":"6month","weight":0.0756},{"period":"1year","weight":0.2437},{"period":"ytd","weight":0.0816}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Black Diamond Therapeutics, Inc., a clinical-stage precision oncology medicine company, focuses on the discovery and development of therapies for patients with genetically defined cancers. The company's lead product candidate, BDTX-1535, a brain-penetrant, mutant selective, irreversible EGFR MasterKey inhibitor, designed to inhibit a family of oncogenic mutations, currently under Phase 1 clinical trial. It also develops BDTX-4933, a brain penetrant RAF MasterKey inhibitor, designed to be a brain penetrant and highly selective and potent inhibitor of oncogenic BRAF Class I, II, III and active RAF dimers, expected to initiate Phase 1 clinical trial. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.139571},{"month":2,"riseRate":0.285714,"avgChangeRate":-0.101126},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.091468},{"month":4,"riseRate":0.714286,"avgChangeRate":0.093724},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.066721},{"month":6,"riseRate":0.571429,"avgChangeRate":0.309855},{"month":7,"riseRate":0.5,"avgChangeRate":-0.00251},{"month":8,"riseRate":0.666667,"avgChangeRate":-0.009829},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.106486},{"month":10,"riseRate":0.5,"avgChangeRate":-0.063219},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.007717},{"month":12,"riseRate":0.166667,"avgChangeRate":-0.108792}],"exchange":"NASDAQ","name":"Black Diamond Therapeutics, Inc.","nameEN":"Black Diamond Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Black Diamond Therapeutics, Inc.(BDTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Black Diamond Therapeutics, Inc.(BDTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Black Diamond Therapeutics, Inc.,BDTX,Black Diamond Therapeutics, Inc.股票,Black Diamond Therapeutics, Inc.股票老虎,Black Diamond Therapeutics, Inc.股票老虎国际,Black Diamond Therapeutics, Inc.行情,Black Diamond Therapeutics, Inc.股票行情,Black Diamond Therapeutics, Inc.股价,Black Diamond Therapeutics, Inc.股市,Black Diamond Therapeutics, Inc.股票价格,Black Diamond Therapeutics, Inc.股票交易,Black Diamond Therapeutics, Inc.股票购买,Black Diamond Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Black Diamond Therapeutics, Inc.(BDTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Black Diamond Therapeutics, Inc.(BDTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}